We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for deve... Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. Show more
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2024 that were previously approved by the Compensation...
Honeywell (NASDAQ:HON) – Honeywell announced the acquisition of CAES Systems for $1.9 billion, focusing on expanding its aerospace and defense technology operations. Under the leadership of...
β FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients β FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients β Sarepta will host an investor...
Adobe (NASDAQ:ADBE) – Adobe exceeded expectations in the last quarter with revenue of $5.31 billion, above analysts’ consensus polled by FactSet of $5.29 billion. Adjusted earnings...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the βGrant Dateβ) that were previously approved by the...
Sarepta Therapeutics Set to Join S&P MidCap 400 PR Newswire NEW YORK, May 29, 2024 NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.55 | -0.360490266763 | 152.57 | 154.9 | 148.205 | 1363715 | 150.92602354 | CS |
4 | 27.93 | 22.5078572004 | 124.09 | 173.1 | 115.74 | 2430550 | 152.99449084 | CS |
12 | 35.47 | 30.4332904333 | 116.55 | 173.1 | 109.91 | 1951206 | 137.0346387 | CS |
26 | 35.29 | 30.2321596847 | 116.73 | 173.1 | 109.91 | 1374077 | 132.75261994 | CS |
52 | 42.95 | 39.3783808563 | 109.07 | 173.1 | 55.25 | 1356152 | 114.68071736 | CS |
156 | 79.1 | 108.475041141 | 72.92 | 173.1 | 55.25 | 1168992 | 108.15892009 | CS |
260 | -2.35 | -1.52231651228 | 154.37 | 181.83 | 55.25 | 1189322 | 108.15746724 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions